Rabia has a background in immuno-genetics and is focussed on bridging the worlds of science, business and technology in the areas of medicine, healthcare, network biology and genomics. Most recently, she was Managing Director for the Discovery Sciences division at Sensyne health, a publicly listed company with a unique partnership model with the NHS. At Sensyne, she established the scientific strategy, built the data science and discovery teams from 4 to 50 in 6 months, and was pivotal to a number of significant pharma partnerships. Under her leadership, the discovery sciences division launched multiple successful products alone or with pharma partners; the development of these products benefitted from Sensyne’s unique access to NHS data resources.
Prior to joining Sensyne Health, Rabia held senior roles at BenevolentAI and Meta. At Meta (acquired by Chan Zuckerberg BioHub), she was pivotal in the partnership with the Intelligence Advanced Research Projects Activity (IARPA) to acquire horizon-scanning technology that used NLP to research the biomedical corpus. At BenevolentAI, she helped shape the discovery strategy, and led the Age-Related Macular Degeneration and Glioblastoma drug discovery programmes and served as the interface between the technical and biological teams alongside Prof. Jackie Hunter.
Rabia regularly presents on embracing the intersection of healthcare and technology to advance better patient outcomes and advocates the importance of STEM in industry and education. She was named as 550 Movers and Shakers in BioBusiness – 19 and 30 Rising Leaders in biotech 2020 . Currently, she is Founder and CEO of Ladder Therapeutics, a foundation stage biotech, a YCombinator company.